Italia markets close in 1 hour 7 minutes
FTSE MIB
35.338,38 -71,75 (-0,20%) Dow Jones
39.910,56 +41,18 (+0,10%) Nasdaq
16.700,67 +2,35 (+0,01%) Nikkei 225
38.787,38 -132,88 (-0,34%) Petrolio
79,23 0,00 (0,00%) Bitcoin EUR
60.928,40 +234,61 (+0,39%)
NBIX May 2024 145.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 11:45AM EDT. Mercato aperto.
| Chiusura precedente | 10,28 |
| Aperto | 10,28 |
| Denaro | 2,10 |
| Lettera | 6,00 |
| Prezzo d'esercizio | 145,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 10,28 - 10,28 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 12 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.